MedTrace Logo

Tolerability and Safety of BDB-001 Injection in Healthy Subjects

NCT05361005 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2022-05-04

No results posted yet for this study

Summary

A clinical study to evaluate the tolerability, PK and PD characteristics of BDB-001 Injection in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

BDB-001 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

Sponsors & Collaborators

  • Beijing Defengrei Biotechnology Co.,Ltd

    collaborator UNKNOWN

  • Staidson (Beijing) Biopharmaceuticals Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-12
Primary Completion
2020-05-08
Completion
2020-05-08

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05361005 on ClinicalTrials.gov